In a new sponsored video, Thermo Fisher Scientific’s Alberto Fernández discusses the company's Accelerator Drug Development solution.
The FDA could make it harder for developers of CAR-T therapies to bring them to market by requiring full randomised controlled trials.
UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with MASH to help measure disease activity.
Eli Lilly has revealed the data it hopes will take BTK inhibitor Jaypirca into frontline use for chronic lymphocytic leukaemia.
Editor's Picks
